On Thursday, Arista Networks Inc (NYSE:ANET)’s shares dwindled -5.19%, and closed at $66.01, as Arista Networks Inc(NYSE:ANET), declared that CFO Kelyn Brannon will leave the corporation for personal reasons. Ms. Brannon has served Arista as CFO since July 2013, playing an instrumental role in taking the corporation public in June 2014 at NYSE.
“Kelyn assisted strengthen our financial foundation as we evolved from a private to a public corporation, which will serve our corporation and our shareholders well for the long term. We thank her for her services and wish Kelyn much success in the future,” said Jayshree Ullal, President and CEO for Arista Networks.
Arista Networks: provides cloud networking solutions. The corporation offers extensible operating systems, a set of network applications, and Ethernet switches. It serves a range of industries, counting Internet companies, service providers, financial services organizations, government agencies, media and entertainment companies, and others. Arista Networks, Inc. markets its products through direct sales force and channel partners, such as distributors, value-added resellers, systems integrators, and original equipment manufacturer partners.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s shares dropped -5.18%, and settled at $99.79, during the last trading session on Thursday, soon as Esperion Therapeutics Inc(NASDAQ:ESPR), declared the closing of its follow-on public offering of 2,012,500 shares of ordinary stock, offered at a price to the public of $100.00 per share, which comprises the exercise in full by the underwriters of their option to purchase 262,500 additional shares of ordinary stock. This exercise brings the net proceeds in the offering to $189.9 million, after deducting underwriting discounts and commissions and estimated expenses payable by Esperion. Esperion intends to use the net proceeds from the offering, in addition to its other existing capital resources, to complete the clinical development of ETC-1002, counting development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.
Esperion Therapeutics: a biopharmaceutical corporation, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products comprise ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, in addition to to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies.
At the end of Thursday’s trade, Tesoro Corporation (NYSE:TSO)’s shares dipped -5.15%, and closed at $86.61, as Tesoro Corporation(NYSE:TSO), release its earnings for the first quarter 2015 after the market closes on Thursday, May 7, 2015. The Corporation will broadcast, live, its conference call with analysts regarding first quarter results and other business matters on Friday, May 8, 2015, at 7:30 a.m. CT.
Tesoro Corporation: through its auxiliaries, engages in petroleum refining and marketing activities in the United States. It operates in three segments: Refining, Tesoro Logistics LP (TLLP), and Retail. The Refining segment refines crude oil and other feed stocks into transportation fuels, such as gasoline, gasoline blend stocks, jet fuel, and diesel fuel, in addition to other products, counting heavy fuel oils, liquefied petroleum gas, petroleum coke, calcined coke, and asphalt.
Banro Corporation (USA) (NYSEMKT:BAA), ended its Thursday’s trading session with - 3.15% loss, and closed at $0.200, after Banro Corporation (USA)(NYSEMKT:BAA), release its year end 2014 financial results by Monday, April 6, 2015 and follow with an investor conference call at 11:00 am EST on Tuesday, April 7, 2015. Dial-in details for the conference call will be comprised of in the April 6 release. The Corporation did not release its financial results recently as the audit of the financial statements has not yet been accomplished.
Banro Corporation: together with its auxiliaries, engages in the exploration, development, and mining of gold properties. The corporation holds a 100% interest in 4 gold properties, counting Twangiza, Namoya, Lugushwa, and Kamituga comprising 13 exploitation permits that cover an area of about 2,612 square kilometers in the South Kivu and Maniema provinces of the Democratic Republic of the Congo.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
